The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy | MicrobiomeTrials← Back to trialsNCT05019885
The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2022-08-26Est. Completion: 2026-06-08
Enrollment target: 12 participants Locations- Mount Sinai Hospital, New York, New York, United States
Other microbiome trials you might be interested in
Dravet Syndrome (DS)Lennox-Gastaut Syndrome (LGS)
The goal of this clinical trial is to learn the best way to switch children with Lennox-Gastaut Syndrome (LGS) or Dravet…
Toronto, CanadaEst. completion Jan 1, 2028
Epilepsy, Temporal LobeDrug Resistant Epilepsy
Participants with drug-resistant epilepsy (DRE) enrolled in this study will receive focused ultrasound (FUS) treatment w…
Melbourne, AustraliaEst. completion Jun 1, 2027